The study will consist of 8 dose cohorts:~Previously untreated patients 20 mg/kg TRU-016 + rituximab.~Relapsed patients, 20 mg/kg TRU-016 + rituximab.~Previously untreated patients 10 mg/kg TRU-016 + rituximab.~Previously untreated patients TRU-016 + obinutuzumab.~Relapsed patients, 20 mg/kg TRU-016 + rituximab + idelalisib.~Patients with CLL on ibrutinib or another BTK inhibitor for a total of more than 1 year who have not had a complete response (CR) will continue receiving ibrutinib or another BTK inhibitor.~Patients with CLL on ibrutinib or another BTK inhibitor with stable disease and in whom the cysteine 481 mutant clone is present at a level >1%, will continue receiving ibrutinib or the alternative BTK inhibitor.~Patients with relapsed or refractory PTCL will receive TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days) + bendamustine for 2 days every cycle for 6 cycles.
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.